Header Logo

Connection

VARSHA V GANDHI to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications VARSHA V GANDHI has written about Protein Kinase Inhibitors.
VARSHA V GANDHI
Connection Strength
2.522
Protein Kinase Inhibitors
  1. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
    View in: PubMed
    Score: 0.320
  2. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021 04 29; 11(4):79.
    View in: PubMed
    Score: 0.253
  3. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
    View in: PubMed
    Score: 0.211
  4. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
    View in: PubMed
    Score: 0.187
  5. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873.
    View in: PubMed
    Score: 0.178
  6. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
    View in: PubMed
    Score: 0.165
  7. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des. 2014; 20(42):6670-81.
    View in: PubMed
    Score: 0.152
  8. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
    View in: PubMed
    Score: 0.152
  9. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.
    View in: PubMed
    Score: 0.149
  10. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500.
    View in: PubMed
    Score: 0.139
  11. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23.
    View in: PubMed
    Score: 0.134
  12. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7.
    View in: PubMed
    Score: 0.113
  13. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80.
    View in: PubMed
    Score: 0.068
  14. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297.
    View in: PubMed
    Score: 0.066
  15. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433.
    View in: PubMed
    Score: 0.052
  16. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
    View in: PubMed
    Score: 0.050
  17. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
    View in: PubMed
    Score: 0.035
  18. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32.
    View in: PubMed
    Score: 0.034
  19. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
    View in: PubMed
    Score: 0.028
  20. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One. 2015; 10(8):e0135962.
    View in: PubMed
    Score: 0.011
  21. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015 Apr 01; 21(7):1537-42.
    View in: PubMed
    Score: 0.010
  22. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.008
  23. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.